Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

October 15, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Epstein-Barr Virus (EBV) Infection
Interventions
OTHER

Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments)

Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).

OTHER

Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin)

Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).

OTHER

Data collection: Patient reported outcome (Fatigue questionnaires)

Data collection: Patient reported outcome (Fatigue questionnaires) at 6 and 12 months.

Trial Locations (1)

4031

RECRUITING

University Hospital Basel, Division of Internal Medicine, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER